A First-in-Class Pan–KRAS-Selective Inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A single inhibitor for all KRAS mutations
Nat Cancer 2023 Aug 01;4(8)1060-1062, RB CorcoranFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.